ACQUISITION OF NET ASSETS OF CELL GENESYS (Tables)

12 Months Ended

Dec. 31, 2011

ACQUISITION OF NET ASSETS OF CELL GENESYS

Schedule of purchase price of the merger

Fair value of BioSante common stock issued (3,369,967 shares)	$	36,800,043
Transaction costs of BioSante		2,431,252
Total purchase price	$	39,231,295

Schedule of purchase price allocation

Cash	$	24,746,346
Investment in Ceregene		3,486,000
In-process research and development		9,000,000
Receivables, equipment and other assets		293,658
Accounts payable and accrued liabilities		1,777,323
Convertible senior notes		16,709,580
Total net assets acquired	$	19,039,101